These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937 [TBL] [Abstract][Full Text] [Related]
10. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma. Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604 [TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B; Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126 [TBL] [Abstract][Full Text] [Related]
13. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123 [TBL] [Abstract][Full Text] [Related]
14. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289 [TBL] [Abstract][Full Text] [Related]
15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Mateos MV; Landgren O Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254 [TBL] [Abstract][Full Text] [Related]
16. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic Advances in the Management of Smoldering Myeloma. Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112 [TBL] [Abstract][Full Text] [Related]